Program
NVG-291
A development code.
Its studies are mostly in Spinal Cord Injuries · Quadriplegia, led by NervGen Pharma.
Furthest: phase 3, since Aug 18, 20263 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NervGen Pharma | 31 open or running | phase 3since Aug 18, 2026 | Mar 15, 2022 | Jul 2027phase 3 · NCT07799532 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 15, 2022First study: phase 1 study in Spinal Cord InjuriesFirst studyNCT05308953 · 74 enrolled · Australia
- Jul 16, 2023Phase 2 study in Spinal Cord InjuriesNCT05965700 · 24 enrolled · United States
- Aug 18, 2026Phase 3 study in QuadriplegiaPhase 3 reachedNCT07799532 · 150 planned · United States, Canada
Ahead
- Jul 2027Primary completion: phase 3 study in QuadriplegiaNCT07799532
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07799532Quadriplegia · United States, Canada | 3 | Recruiting | Jul 2027 | 150 |
| NCT05965700Spinal Cord Injuries · United States | 2 | Completed | Dec 31, 2025 | 24 |
| NCT05308953Spinal Cord Injuries · Australia | 1 | Completed | Jun 4, 2023 | 74 |
How it is read
Names in the registry
- “NVG-291”, 3 entries
Codes read as this program: NVG291.
Conditions, from the studies’ own filings
- Spinal Cord Injuries, 2 studies
- Quadriplegia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.